 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
11 News |  |
- eprenetapopt (APR-246) / Aprea, 2aG4 / Avid Bioservices
[VIRTUAL] Inhibiting Growth of Human Triple-Negative Breast Cancer Cells by Activating Mutant p53 Protein Alone or in Combination With a Phosphatidylserine-Targeting Antibody (On-Demand) - Feb 2, 2021 - Abstract #ENDO2021ENDO_2168;
For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
- | 2aG4 / Avid Bioservices
Journal: Drugging MYCN oncogenic signalling through the MYCN-PA2G4 binding interface. (Pubmed Central) - May 29, 2020
Here, we reveal the oncogenic role of a novel MYCN target and binding protein, proliferation-associated 2AG4 (PA2G4)...Treated tumors showed reduced levels of both MYCN and PA2G4. Our findings demonstrate a critical role for PA2G4 as cofactor in MYCN-driven neuroblastoma and highlight competitive inhibition of the PA2G4-MYCN protein binding as a novel therapeutic strategy in the disease.
- Tarvacin (bavituximab) / Oncologie, 2aG4 / Peregrine
Activation of toll-like receptors via PS-targeting monoclonal antibodies (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_703;
Overall these data support that one mechanism of innate immune activation induced by PS-targeting mAbs is through TLR2 stimulation on myeloid cells. Future studies are focused on validating these results in vivo using Tlr-deficient and b2gp1-deficient mice.
- | APR-246 / Aprea
Preclinical, Journal, Combination therapy, IO Biomarker: APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice. (Pubmed Central) - Sep 21, 2019
Metastasis of human mtp53-expressing TNBC cells to the lungs of nude mice is inhibited by the treatment that combines activation of mtp53 with targeting of phosphatidylserine residues on tumor blood vessels. We contend therefore that our findings strongly support the use of combination treatment involving mtp53 activation and immunotherapy in patients with TNBC.
- | Nexavar (sorafenib) / Bayer, Amgen
Journal: Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. (Pubmed Central) - Feb 2, 2018
We contend therefore that our findings strongly support the use of combination treatment involving mtp53 activation and immunotherapy in patients with TNBC. Overall, these results strongly support the combination of bavituximab with sorafenib as a promising systemic therapeutic strategy for the treatment for advanced HCC patients.